<br>        Inclusion Criteria:<br><br>          -  Male and female subjects aged =6 years at the time of screening, with an Informed<br>             Consent Form signed by patient and if appropriate by parent/legal guardians, prior to<br>             any study-related procedure.<br><br>          -  Confirmed diagnosis of CF by the presence of one or more clinical features of CF in<br>             addition to a quantitative pilocarpine iontophoresis sweat chloride test of >60 mEq/L;<br>             or identification of well-characterized disease-causing mutations in each CFTR gene;<br>             or an abnormal nasal transepithelial potential difference characteristic of CF.<br><br>          -  P aeruginosa must be present in sputum or deep throat swab (or bronchoalveolar lavage<br>             [BAL]) at the screening visit and within 6 months prior to screening.<br><br>        Exclusion Criteria:<br><br>          -  History of sputum (or BAL) culture yielding Burkholderia cepacia (B cepacia) within 2<br>             years prior to screening and/or sputum culture yielding B cepacia at screening.<br><br>          -  FEV1 <25% of normal predicted values for age, sex, and height based on Knudson<br>             criteria at screening.<br><br>          -  Hemoptysis of more than 60 cc at any time within 30 days prior to study drug<br>             administration.<br><br>          -  Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.<br><br>          -  GFR<60ml/min/1.73m2 calculated with the Formula by Schwartz, BUN 40 mg/dl or more, or<br>             an abnormal urinalysis defined as 2+ or greater proteinuria.<br><br>          -  History of tinnitus or pathologic audiometry<br><br>          -  diagnosis of Allergic bronchopulmonary aspergillosis (ABPA) at screening<br><br>          -  Initiation of treatment with macrolide antibiotics within 28 days prior to study drug<br>             administration (subjects may be taking macrolide antibiotics at the time of<br>             enrollment, but they must have initiated treatment at least 28 days prior to study<br>             drug administration).<br><br>          -  Use of loop diuretics within 7 days prior to study drug administration.<br><br>        Other protocol-defined inclusion/exclusion criteria may apply<br>      ;<br>        Inclusion Criteria:<br><br>          -  Male and female subjects aged =6 years at the time of screening, with an Informed<br>             Consent Form signed by patient and if appropriate by parent/legal guardians, prior to<br>             any study-related procedure.<br><br>          -  Confirmed diagnosis of CF by the presence of one or more clinical features of CF in<br>             addition to a quantitative pilocarpine iontophoresis sweat chloride test of >60 mEq/L;<br>             or identification of well-characterized disease-causing mutations in each CFTR gene;<br>             or an abnormal nasal transepithelial potential difference characteristic of CF.<br><br>          -  P aeruginosa must be present in sputum or deep throat swab (or bronchoalveolar lavage<br>             [BAL]) at the screening visit and within 6 months prior to screening.<br><br>        Exclusion Criteria:<br><br>          -  History of sputum (or BAL) culture yielding Burkholderia cepacia (B cepacia) within 2<br>             years prior to screening and/or sputum culture yielding B cepacia at screening.<br><br>          -  FEV1 <25% of normal predicted values for age, sex, and height based on Knudson<br>             criteria at screening.<br><br>          -  Hemoptysis of more than 60 cc at any time within 30 days prior to study drug<br>             administration.<br><br>          -  Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.<br><br>          -  GFR<60ml/min/1.73m2 calculated with the Formula by Schwartz, BUN 40 mg/dl or more, or<br>             an abnormal urinalysis defined as 2+ or greater proteinuria.<br><br>          -  History of tinnitus or pathologic audiometry<br><br>          -  diagnosis of Allergic bronchopulmonary aspergillosis (ABPA) at screening<br><br>          -  Initiation of treatment with macrolide antibiotics within 28 days prior to study drug<br>             administration (subjects may be taking macrolide antibiotics at the time of<br>             enrollment, but they must have initiated treatment at least 28 days prior to study<br>             drug administration).<br><br>          -  Use of loop diuretics within 7 days prior to study drug administration.<br><br>        Other protocol-defined inclusion/exclusion criteria may apply<br>      ;<br>        Inclusion Criteria:<br><br>          -  Male and female subjects aged =6 years at the time of screening, with an Informed<br>             Consent Form signed by patient and if appropriate by parent/legal guardians, prior to<br>             any study-related procedure.<br><br>          -  Confirmed diagnosis of CF by the presence of one or more clinical features of CF in<br>             addition to a quantitative pilocarpine iontophoresis sweat chloride test of >60 mEq/L;<br>             or identification of well-characterized disease-causing mutations in each CFTR gene;<br>             or an abnormal nasal transepithelial potential difference characteristic of CF.<br><br>          -  P aeruginosa must be present in sputum or deep throat swab (or bronchoalveolar lavage<br>             [BAL]) at the screening visit and within 6 months prior to screening.<br><br>        Exclusion Criteria:<br><br>          -  History of sputum (or BAL) culture yielding Burkholderia cepacia (B cepacia) within 2<br>             years prior to screening and/or sputum culture yielding B cepacia at screening.<br><br>          -  FEV1 <25% of normal predicted values for age, sex, and height based on Knudson<br>             criteria at screening.<br><br>          -  Hemoptysis of more than 60 cc at any time within 30 days prior to study drug<br>             administration.<br><br>          -  Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.<br><br>          -  GFR<60ml/min/1.73m2 calculated with the Formula by Schwartz, BUN 40 mg/dl or more, or<br>             an abnormal urinalysis defined as 2+ or greater proteinuria.<br><br>          -  History of tinnitus or pathologic audiometry<br><br>          -  diagnosis of Allergic bronchopulmonary aspergillosis (ABPA) at screening<br><br>          -  Initiation of treatment with macrolide antibiotics within 28 days prior to study drug<br>             administration (subjects may be taking macrolide antibiotics at the time of<br>             enrollment, but they must have initiated treatment at least 28 days prior to study<br>             drug administration).<br><br>          -  Use of loop diuretics within 7 days prior to study drug administration.<br><br>        Other protocol-defined inclusion/exclusion criteria may apply<br>      ;<br>        Inclusion Criteria:<br><br>          -  Male and female subjects aged =6 years at the time of screening, with an Informed<br>             Consent Form signed by patient and if appropriate by parent/legal guardians, prior to<br>             any study-related procedure.<br><br>          -  Confirmed diagnosis of CF by the presence of one or more clinical features of CF in<br>             addition to a quantitative pilocarpine iontophoresis sweat chloride test of >60 mEq/L;<br>             or identification of well-characterized disease-causing mutations in each CFTR gene;<br>             or an abnormal nasal transepithelial potential difference characteristic of CF.<br><br>          -  P aeruginosa must be present in sputum or deep throat swab (or bronchoalveolar lavage<br>             [BAL]) at the screening visit and within 6 months prior to screening.<br><br>        Exclusion Criteria:<br><br>          -  History of sputum (or BAL) culture yielding Burkholderia cepacia (B cepacia) within 2<br>             years prior to screening and/or sputum culture yielding B cepacia at screening.<br><br>          -  FEV1 <25% of normal predicted values for age, sex, and height based on Knudson<br>             criteria at screening.<br><br>          -  Hemoptysis of more than 60 cc at any time within 30 days prior to study drug<br>             administration.<br><br>          -  Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.<br><br>          -  GFR<60ml/min/1.73m2 calculated with the Formula by Schwartz, BUN 40 mg/dl or more, or<br>             an abnormal urinalysis defined as 2+ or greater proteinuria.<br><br>          -  History of tinnitus or pathologic audiometry<br><br>          -  diagnosis of Allergic bronchopulmonary aspergillosis (ABPA) at screening<br><br>          -  Initiation of treatment with macrolide antibiotics within 28 days prior to study drug<br>             administration (subjects may be taking macrolide antibiotics at the time of<br>             enrollment, but they must have initiated treatment at least 28 days prior to study<br>             drug administration).<br><br>          -  Use of loop diuretics within 7 days prior to study drug administration.<br><br>        Other protocol-defined inclusion/exclusion criteria may apply<br>